Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


NDSAC Interim Recommendations on fluticasone propionate nasal spray

A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on December 1, 2019 with the following interim recommendations made:

 

  • Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays - be granted Schedule III status.

 

  • Fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays -  be granted Schedule II status

 

Any objections to these interim recommendations must be received by the NAPRA office by end of day January 8, 2020. Questions or comments should be directed to the Manager, Professional and Regulatory Affairs, Sarah Marshall via email at smarshall@napra.ca.

Date: